About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | MicroRNAs in Patients With Neurofibromatosis Type 1

MicroRNAs in Patients With Neurofibromatosis Type 1

NCT01595139·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Ann & Robert H Lurie Children's Hospital of Chicago

Age

2–21

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Patients ages 2 years to 21 years.
Patients with NF-1 being followed in the Neurofibromatosis Clinic.
Patients have had MRI imaging in the 24 months prior to enrollment on the study.
Patients may have known concurrent malignancies such as plexiform neurofibroma.
Patients and/or parents/legal guardians must have signed an informed consent and assent when applicable.

You may not be if

Patients who have had prior tumor-directed therapy (including chemotherapy and/or radiation)
Patients with a prior or current diagnosis of a malignant peripheral nerve sheath tumor.
Patients who are considered too ill to participate as determined by their treating physician
Patients who are pregnant or lactating

The record

StatusCompleted

PhaseNo phase

Taking part9

StartedFeb 2012

UpdatedDec 6, 2024

Conditions

Glioma Neurofibromatosis Type 1

Where1

Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States